Loading...

Member Profile

Steminent Biotherapeutics Inc. (SBI) aims to advance the translation of stem cell technology into effective cellular treatments for unmet or underserved medical needs. SBI has established its proprietary AD-MSCs (Adipose-Derived Mesenchymal Stem Cells) technology platform, Stemchymal®, and is one of the global leading stem cell therapy companies in its phase II clinical stage in Taiwan, US and Japan. The Taiwan phase II clinical trial for spinocerebellar ataxia treatment is completed and under data analysis at this moment. With unique patented cell properties, Stemchymal® cell product lends itself to safe and efficacious allogeneic use and received Orphan Drug Designation (ODD) for Spinocerebellar Ataxia (SCA) treatment from US Food and Drug Administration and Japan Pharmaceuticals and Medical Devices Agency (Japan ODD is received by licensed Japanese partner).


Product Pipelines

Please move your mouse cursor over abbreviations with periods to see their full names.

Company Milestones

   2009 Steminent Biotherapeutics Inc.(SBI) was founded.
   2011 SBI received Taiwan phase I clinical trial approval for SCA treatment.
   2014 SBI completed the Taiwan phase I clinical trial for SCA treatment.
   2015 SBI received Orphan Drug Designation for SCA treatment from USFDA.
   2015 SBI received Taiwan phase I clinical trial approval for osteoarthritis knee treatment.
   2016 SBI received Taiwan phase II clinical trial approval for SCA treatment.
   2016 SBI completed the out-licensing with its Japanese partner.
   2018 SBI received USFDA phase II clinical trial approval for SCA treatment.
   2018 SBI received Japan PMDA phase II clinical trial approval for SCA treatment.
   2018 SBI completed the Taiwan phase I clinical trial for osteoarthritis knee treatment.
   2018 SBI received Taiwan phase I clinical trial approval for ALF treatment.
   2020 SBI completed the Taiwan phase II clinical trial for SCA treatment and is now processing data analysis; Japan phase II clinical trial for SCA treatment is ongoing;SBI completed the out-licensing with its Korean partner.